2028Pilots into operating systems
2028 is the year the plan must move beyond promising starts. Systems launched in 2027 must become real operating capabilities: the goal is to move from standards to adoption, from pilots to functioning workflows, and from commitments to routine practice.
Last updated: October 1, 2026
Suggested philanthropic spend
$480M
Cumulative
$860M
Prevent
$130M
Detect
$65M
Respond
$285M
2028 Pillar Objectives
Prevent
- Translate the foundational work of 2027 into real uptake and recurring practice across providers, developers, and high-risk research institutions.
- Expand screening, KYC, safeguards, bio-audits, accident reporting, and misuse monitoring from pilot form into routine operating systems.
Detect
- Complete the first meaningful wave of pathogen-agnostic surveillance deployment and demonstrate that anomaly-detection and escalation workflows can function in practice.
Respond
- Move from planning into early operational readiness for PPE delivery, built-environment pilots, MCM pipelines, and coordinated response exercises.
Milestones
Show:
·
PreventKnow Your Customer (KYC)
Begin widespread KYC adoption across high-risk biological vendors and services
PreventAIxBio Safeguards
Make LLM, biological AI model, and autonomous-lab biorisk evaluation routine for relevant developers
PreventResearch Governance
Scale bio-audits, accident reporting, pre-publication biorisk review, and institutional participation into routine practice
Operationalize provider-to-provider and provider-to-government threat sharing and misuse monitoring
DetectGlobal Early Warning
Complete first-wave sentinel deployment and integrate anomaly-detection, investigation, and response workflows
DetectDiagnostics & Testing
Advance pathogen-agnostic diagnostics through development and seek emergency authorization for lead platforms
Build initial essential-workforce PPE stockpiles held for public distribution and exercise rapid delivery systems
Continue biohardening pilots and test NPI / building-response playbooks in public settings
Advance government-led platform vaccine, therapeutic, and diagnostic programs while readying trial and manufacturing infrastructure
RespondGlobal Response Coordination